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ABSTRACT
The treatment of most cancers can still be considered inadequate despite the steady
progress being made. A prime example of this issue is with epithelial ovarian cancers; this
disease presents a significant issue, with a 5-year survival rate of 46% and a survival rate of 28%
in patients that develop metastatic disease. Since ovarian cancer has such a high mortality rate,
effective treatment modalities are necessary to prolong the quality of life after diagnosis.
Psychosocial stress is related to the progression, proliferation, and migration in cancer patients,
but the mechanisms of this relationship are not fully understood. The present in vitro study
investigated the ability of oxytocin, a neuropeptide associated with social support, to attenuate
the stress response. Catecholamines, a subclass of stress hormones, were used to simulate the
stress induced inflammation process in ovarian cancer cells. To evaluate oxytocin’s capacity to
attenuate the stress response, the ovarian cancer cell lines SKOV3, HEYA8, OVCAR8, and
OV432 were separately treated with the presence or absence of catecholamines with the addition
of oxytocin. Protein expression of the oxytocin receptor was investigated using a western blot
protocol. Oxytocin receptor, oxytocin, and IL-6 mRNA expression was evaluated by quantitative
PCR. Treatment with Oxytocin attenuated the inflammatory response resulting from
catecholamine treatment. The oxytocin receptor gene and protein were present in each cell line,
suggesting that oxytocin has an anti-inflammatory role in the tumor microenvironment in ovarian
cancer patients. These results provide a mechanism by which social support, working through the
release of oxytocin, promotes an anti-inflammatory process in ovarian cancer patients. This study
may shed light into new pharmacological approaches for the treatment of ovarian cancer.
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PURPOSE AND SIGNIFICANCE
This research aims to characterize the function of oxytocin/ oxytocin receptor (OXT/OXTR) in
human ovarian cancer cells. Given the presence of OXT in the ascites fluid of ovarian cancer
patients, and the inverse correlation found between OXT levels and inflammation makers (as
reported to us from the Lutgendorf lab), we will evaluate a possible cellular mechanism in
ovarian cancer cells. The increased levels of oxytocin found may serve to modulate the inherent
inflammatory state of the cancer cells to potentially modulate tumor growth and progression. We
will evaluate if OXT/OXTR in ovarian cells is present to modulate the inflammatory state. We
believe OXT/OXTR expression will be increased during inflammation and that oxytocin may act
as a stress buffer in this situation. By investigating the correlation between any changes observed
in these cells with oxytocin treatment it may open new doors for ovarian cancer treatment. By
understanding the mechanism potentially at work we may be able to advance a pharmacological
approach to both pre-clinical and clinical models.
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CHAPTER ONE: INTRODUCTION
Definition of Stress and Relevant Pathways
When receiving the diagnosis of cancer, and life thereafter, the patient can find many of
the aspects of the disease to be stressful, such as the physical, emotional and social effects. This
stress disrupts the body’s homeostasis and in this context described as “the state of being
threatened, or perceived as being threatened” [1, 2]. This disruption of homeostasis is associated
with activation of the body’s two major stress systems, the sympathetic nervous system and the
hypothalamic- pituitary-adrenal (HPA) axis[3]. The physiological reaction to stress includes
arousal of the HPA axis above the normal level, which produces the secretion of cortisol and
stimulation of the sympathetic nervous system (SNS) which promotes the secretion of
catecholamines[2, 4]. Noradrenergic pathways from the SNS have been linked with the growth
and progression of ovarian cancer. Further, bio-behavioral factors have been linked to
norepinephrine levels in the tumor microenvironment; concentrations in ascites are unknown,
although spillover from perivascular neuro-muscular junctions could be a possible pathway in
ovarian cancer patients[5].

The idea that psychosocial elements influence the progression and

growth of cancer has been an accepted theory for many generations. To validate this hypothesis
epidemiological and clinical studies have illustrated that there is a link between chronic stress,
being in a state of depression and being socially isolated with cancer growth [3, 6-9]. Current
studies of the microenvironment of carcinomas have distinguished particular signaling pathways
that effect cancer progression and metastasis from stress molecules (catecholamines). It is
relevant to note that catecholamines have been shown to increase the secretion of inflammatory
molecules from cancer cells, including ovarian cancer cells[2, 3].
2

Molecules of Interest Released During “Stress”
Stress can be acute or chronic in nature[10]. Concerning the psychological stress of
cancer diagnosis and treatment, chronic stress is of importance to cancer patients and this present
study. When an individual experiences chronic and continuous stress, the body’s system stays in
a condition of elevated work. This is harmful in regards to the body’s management of stress
response systems, as well as other internal systems [3]. Individuals with chronic stress are known
to have raised levels of the catecholamines norepinephrine (NE) and epinephrine (E) [11]. Of
note, studies on this phenomena have shown that chronic stress stimulates tumor growth,
angiogenesis, and metastasis [3, 12, 13].
Previously, the pro-inflammatory/pro-angiogenic cytokine interleukin-6 (IL-6) has been
associated with chronic stress[2]. Specifically, those who have documented chronic stress have
been shown to have above average levels of circulating IL-6 [14]. Further, behavioral
components have been linked with both the levels of circulating and ascites IL-6 in ovarian
cancer patients [2, 15]. The catecholamine E has been demonstrated to increase IL-6 expression
in adipose tissue [16], and NE treatment of myocytes increases IL-6 expression [17]. Most
importantly, catecholamine treatment lead to elevated expression of IL-6 in ovarian cancer
cells[2]. The effect of NE and E on IL-6 expression was inhibited by using a β-adrenergic
receptor antagonist, however an α-adrenergic receptor antagonist was not able to elicit the same
effect [2]. This is evidence that relevant stress hormones activate β-adrenergic receptors on
ovarian cancer cells[2, 18]. This receptor pathway increases the kinase activity of Src, this
increases transcription of the IL-6 promoter and as a result increased production of IL-6
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protein[2]. To clarify, Src tyrosine kinase is activated through phosphorylation via the
cAMP/PKA signal cascade, which is required for increased IL-6 expression[2].

Effects of Elevated IL-6 in the Microenvironment Due to Stress
IL-6 is elevated in chronically stressed ovarian cancer patients, [14]. However, the
mechanism that regulates IL-6 secretion, as well as its influence in the tumor microenvironment
remain to be determined. High levels of IL-6 are often observed in the serum of ovarian cancer
patients[2]. Further, this finding is correlated with a poor outcomes and increased tumor size [19,
20]. Ovarian cancer cells express β-adrenergic receptors, and stimulating these receptors with NE
produces increased expression of vascular endothelial growth factor (VEGF), an important proangiogenic factor [12, 21]. Angiogenesis is the formation of new blood vessels, which involves
the migration, and growth of endothelial cells. This process is associated with VEGF, and is
required for tumor growth and ascites formation[2]. This is regulated by the presence or absence
of pro-angiogenic and anti-angiogenic molecules [13, 22].
IL-6 released by ovarian cancer cells further facilitates tumor cell growth, and metastasis,
as well as chemotherapy resistance [2, 23-25]. The receptor for IL-6 has been shown to be
present on endothelial cells in the ovary[26]. Treatment of ovary endothelial cells with IL-6 invitro results in increased cell migration, which implicates its role in as a pro-angiogenic factor invivo [26].
Social Support has been Shown to Act as a Protective Factor
It has been suggested that social support can act as a buffer, or protective factor for the
progression and metastasis of cancer, and could be associated with cancer survival advantage.
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Researchers deem social support important when dealing with a crisis, including psychological
adjustment to cancer [27-30]. In a study with breast and gynecological cancer survivors it was
observed that social support was a strong determinant on the quality of life[31]. Further, it was
seen that social support was positively correlated with health-related quality of life in breast
cancer patients[32]. Social isolation in similar circumstances yielded important findings as well.
Social isolation, meaning the lack of friends, nuclear and extended family, after breast cancer
diagnosis was correlated to poorer outcomes[33]. It would appear that social support acts as
buffer to progression of disease. The importance of social support was illustrated by research
showing that there is a correlation between social support and quality of life in both
gynecological and breast cancer survivors. [33-35]. Furthermore, social support is instrumental
in coping with psychological issues that stem from the cancer diagnosis, such as anxiety and
depression. These psychological issues are seen often in cancer patients and can contribute to
physiological stress[6]. These results taken together suggest that social support may be a
protective factor in cancer progression and metastasis, pointing to the importance of underlying
physiological mechanisms linking social support to the tumor microenvironment[8, 9, 30, 36].

How Oxytocin is Released and Circulated in the Body
Oxytocin (OXT) has been shown to be active in the neurobiological mechanism that
promotes social attachment and bonding. OXT is known for its traditional roles in parturition and
lactation [37]. OXT is synthesized in the paraventricular nucleus (PVN) and supraoptic nucleus
of the hypothalamus[38]. Magnocellular oxytoningeric neurons in PVN send their terminals to
the posterior pituitary where they release oxytocin into portal circulation [38, 39]. Parvocellular
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oxytonergic neurons in the PVN send axons to multiple brain and spinal cord areas important for
autonomic nervous system control and processing of painful stimuli[40]. These projections
include other hypothalamic nuclei, the median eminence, the amygdala, hippocampus, locus
coerulues, striatum, raphe nuclei, the dorsal motor nucleus of the vagus nerve, and the nucleus
tractus solitarius [40]. Recent studies have demonstrated that OXT plays a role in social
behaviors and the stress response [41, 42]. Specifically, oxytocin is involved in affiliative
behaviors such as maternal care, sexual behavior, monogamous social bond formation, and social
recognition [41]. The release of OXT to the bloodstream and relative projections from affiliative
behaviors suggests multiple pathways OXT may be involved in, in both the CNS and local
environments[43-45].
While the exact role of OXT in affiliative social interactions remain under investigation,
it has been hypothesized that OXT may counter SNS activation under conditions of social
recognition or affiliation, thereby buffering the stress response and facilitating affiliative
behaviors [46].

Why Oxytocin is the Molecule of Interest
The peptide oxytocin (OXT) has been suggested to be active in a mechanism underlying
the positive results associated with social support that influence cancer progression[47-49]. OXT
is known for its use to induce labor by targeting the uterus[37]. Ovarian tissues and other parts
of the female reproductive organs have been shown to express oxytocin receptors (OTR)[37].
Thus, OXT has the potential to have a role in regulation of the ovarian tumor microenvironment.
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The oxytocin receptor (OTR) is a 389 amino acid polypeptide that has seven
transmembrane domains. This receptor is a G protein coupled receptor [50]. The oxytocin
receptor is present in two different lengths, one size in the breast and a larger size in the ovaries,
endometrium and myometrium [50]. One of the known roles of OXT, as discussed above, is its
role in milk ejection reflex. The stimulation of the infant suckling on the nipple generates a
pathway that starts at the nipple; the impulse is then transmitted to the spinal cord, and from
there to the secretory oxytonergic neurons in the hypothalamus[37]. These neurons have high
frequency burst activity, which leads to a large release of OXT into the blood stream, which then
migrates to the breast[37].

The Link Between OXT and Cancer Cells
OXT receptors are present in numerous breast cancer and other breast related cell lines.
The activation of the OXT system might be the reason breast feeding is linked to a lower
occurrence rate of breast cancer among mothers that breastfed compared to those who did not;
specifically breast cancer after menopause [51]. OXT receptors in human breast tumors and
breast cell lines reacted to OXT by a buildup of calcium within the cell, activation of ERK-2
phosphorylation, and PGE2synthesis[52].
It is believed that the ovary is a site of OXT production for local use [53]. This local
oxytocin is believed to have a role in fertilization and maturation of the embryo in humans [54].
A hypothesis of this present study is that local oxytocin is released by ovarian cancer cells,
which has the potential to be active in an anti-inflammatory pathway, as well as influencing the
synthesis of PGE2.
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In the recent study by the Lutengorf lab and colleagues, there was a significant positive
relationship between social attachment and survival advantage for patients with ovarian
cancer[9]. Thus, although the clinical relevance has been observed, the mechanisms linking
social attachment and survival are not fully understood. The present study seeks to define these
mechanisms in vitro better understand the association between social support and ovarian cancer
outcomes.

Oxytocin has the Ability to Inhibit Cancer Progression and has Systemic AntiInflammatory Effects
Affiliative social behavior, through the release of OXT, has been observed to inhibit
cancer progression in animal models. Specifically, it inhibits proliferation, migration, and
invasion of cancer cells as well as increased expression of E-Cadherin when mice inoculated
with SCOV3 cells were treated with OXT [47]. Further, OXT decreased intraperitoneal
dissemination of the tumor. Intraperitoneal dissemination is a common pathway of tumor
progression that results in the spread of the tumor and the accumulation of ascites fluid. The
increased expression of E-Cadherin has an important function in cell adhesion, the loss of its
function is linked to greater tumor metastasis[55].
To examine mechanisms of this phenomenon in-vivo the OXT effect on the CNS should
be examined. It is possible that OXT reduces CNS activity while increasing peripheral nervous
system (PNS) activity, though the reason is not well understood [45]. When the parasympathetic
nervous system is activated, there is reduced inflammation and oxidative stress in models of
acute tissue injury and inflammation [56]. Mechanistic explanations for the potential stress
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buffering role of OXT come from neurophysiological research suggesting that OXT can enter the
pituitary portal system through the median eminence to directly affect secretion of anterior
pituitary hormones including adrenocorticotropic hormone (ACTH), growth hormone, and
prolactin [57]. Studies have also found species-specific effects indicating that OXT causes short
term increases in ACTH and corticosterone secretion in rats, but inhibits these hormones in
humans and nonhuman primates, which does not offer much of an explanation for the broad antiinflammatory theory[58].Other lines of research indicate that long term OXT treatment also
lowers corticosterone concentration, and increases cholecystokinin levels. This suggests that
OXT may be decreasing SNS activity and increasing vagal activity, implying a general shift
from sympathetic to parasympathetic activation [45]. Other research further demonstrates that
OXT administration causes a shift toward vegetative function, including increased energy
storage. For example, Intracerebroventricular injections of OXT can promote the release of the
gastrointestinal hormones, insulin and glucagon, through activation of vagal efferents that
innervate the GI tract and pancreas [45, 59]. This research supports the hypothesis that OXT
counters the SNS, but the systemic actions may not be a full explanation for phenomena
observed, such as wound healing and decreases of inflammation across a variety of disease
states.

Oxytocin can Influence the Cell Microenvironment
In addition to its CNS and systemic actions, OXT is produced locally in a variety of
peripheral tissues in both sexes, suggesting that this peptide may be involved in the basic
physiological functions of several organs[37]. Recent research has revealed a novel effect of
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OXT on various cancer cell lines [48, 60]. In this situation, OXT functions as a growth regulator
by activating the oxytocin receptor (OTR). When the OTR is stimulated two different pathways
can be activated. There can be an increase or inhibition of cell proliferation because of the OTRs
ability to activate either the Gi or Gq proteins[61]. The Gq pathway triggers the hydrolysis of
PIP2 by PLC, this increases the cystolic calcium level[61]. The increase in calcium increases the
proliferation and growth of some cancer cells. The Gi pathway inhibits PKA-induced tumor
growth and increases the expression of p21Waf1 via the ERK pathway. This pathway inhibits cell
growth[61]. In vitro, OXT was able to inhibit the growth and multiplication of cancer cells, this
was observed in cancerous cells of both epithelial and bone origins. These cells all expressed
OTR [48, 62]. The ability of OXT to inhibit proliferation was observed in mouse and rat ovarian
carcinomas in vivo [47]. This is an important finding as this study aims to define a pathway that
could explain this result. These results are not always the case, in other cancer cell lines
treatment with OXT increased growth [63]. The signal pathway for growth inhibition or
stimulation appears dependent on OXT/OTR binding to Gi or Gq. OXT can inhibit growth
through the activation of the cAMP-PKA pathway through binding and activating the Gi
pathway. The growth can occur through the activation of the Gq protein which when activated
increases intracellular calcium and tyrosine phosphorylation. This Gq activation was the known
and accepted function of OXT for many years [63, 64]. The unexpected role of OXT in
managing cell growth open new perspectives on the role of the OXT/OTR system in various
cancer cells, noting that many cancer cells of different origins express OTR. This suggests the
potential importance of peripheral OXT in local regulation of tumor growth and metastasis.
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These considerations lead to the hypothesis that positive social environment may influence the
progression of ovarian cancer at a local level.
OTR expression has been observed in breast cancer cells (as discussed above),
endometrial cancer cells, glial tumor cells, immune cells, and in neuroblastoma cells. In these
tumors OXT was able to inhibit their growth [48, 65-68]. It is of importance to note that there
was an increase in cell growth after stimulating the OTR in small cell carcinoma of lung cell
lines and choriocarcinoma cell lines, which is probably mediated through the Gq pathway [63,
69]. Speculation of why the OTR-mediated effect varies in many types of cancer, though the
inhibition of cancer proliferation, growth, and metastasis by OXT presents a possible
pharmacological pathway.
Previous data has shown that in individuals with ovarian cancer the influence of
psychosocial well-being was correlated with positive outcomes[9]. OXT has also been
demonstrated to inhibit inflammatory molecules of interest such as IL-6 and VEGF, across a
wide range of medical diseases, including ovarian cancer[15, 70]. Preliminary data from
Lutgendorf and colleagues has shown that higher levels of OXT in ascites are associated with
higher quality of life, psychological well-being, and positive affect. Defining the
biopsychological mechanism, which explains why social support has been shown to increase
quality and length of life in ovarian cancer patients, is the overarching goal of this study.
While pathway mechanisms and possibilities remain controversial[61], research
investigating the activation of oxytocinergic systems through administration of OXT has
provided evidence for the existence of an OXT pathway that could convey protection against the
progression of ovarian cancer[9, 47]. Thus, one possible mechanism mediating the beneficial
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effect of positive social environment on ovarian cancer progression is the activation of a local
oxytocinergic system that modulates inflammatory and oxidative stress pathways.

The known Oxytocin Anti-Inflammatory and Anti-oxidant Pathways
Although there is research supporting the notion that OXT counters SNS activity, it does
not explain the anti-inflammatory pathways observed in many in-vitro and in-vivo models.
Treatment with OXT was able to enhance wound healing, possibly through increased insulin-like
growth factor production [71]. In the carrageenan hind paw inflammation model, OXT was
found to increase nociceptive thresholds and decrease both edema and tissue myeloperoxidase
activity [72]. The level of Myeloperoxidase (MPO) activity in tissue is a marker for neutrophil
recruitment into the intravascular space, which increases inflammation [73]. The release of
reactive oxygen species by MPO activity from infiltrating neutrophils contributes to many
inflammatory conditions through damage to cell membranes, lipid peroxidation, and activation
and recruitment of macrophages [74]. OXT administration has also been shown to decrease MPO
activity in acetic acid induced colitis in rats [75]. In the same study, peripheral OXT
administration inhibited circulating TNF-α. TNF-α is responsible for increased neutrophil
infiltration during conditions of acute inflammation through upregulation of the chotactic factor,
MCP-1, on circulating leukocytes and endothelial cells [76]. This suggests that OXT decreases
TNF-α levels, which could be responsible for the observed decreases in tissues MPO activity.
Findings from our laboratory suggest that OXT receptors exist on monocytes,
macrophages, endothelial cells, and smooth muscle cells, and that OXT inhibits TNF-α
stimulated NAD(P)H-oxidase activation in these cells in vitro[77]. However, expression of
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OXT/OTR as well as if OXT exerts potent inhibitory effects on proangiogenic and proinflammatory molecules released by ovarian cancer cells such as IL-6, VEGF, and TNF-α
remains unknown.
The mechanism responsible for the inhibitory effects of OXT requires clarification. Some
experimental findings have suggested that the anti-inflammatory and anti-oxidant effects of OXT
are due to CNS mechanisms, while others have excluded this possibility by demonstrating that
administration of OXT has no such effects [78]. Administration of high doses of OXT can induce
glucocorticoid release and some authors have suggested that the observed anti-inflammatory
actions of OXT are mediated by increases in endogenous steroids [79]. However, others have
shown similar effects at lower doses that were unlikely to impact glucocorticoid levels [72].
The present study evaluated the possibility that OXT acts directly on peripheral OTRs to
dampen inflammatory and oxidative stress effects through purely local mechanisms. As
mentioned above, support for this hypothesis comes from research suggesting OTR activation
can inhibit IL-6 protein secretion in both THP-1 macrophages and endothelial cells [77]. OTR
promoter region is co-localized with those of pro-inflammatory cytokines meaning that this
peptide may influence transcription of inflammatory genes [80]. The most likely explanation for
the observed anti-inflammatory and anti-oxidant effects of OXT in-vivo is the down regulation of
pro inflammatory cytokines and reactive oxygen species production. One drawback of this
hypothesis is that at high, but physiologically relevant doses, OXT has significant affinity for the
vasopressin receptor [81]. The effects of vasopressin receptor activation can be just as important
to those of OTR in researching the effects of OXT, depending on ovarian cancer gene expression
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of vasopressin receptor. Further, dose response to OXT has not been studied in the ovarian
cancer cell lines being used relative to IL-6 secretion.
As discussed above, when evaluating cancer prognosis it is believed that psychological
factors play a role in cancer growth and progression[3]. The lack of social support and the
feeling of hopelessness are believed to effect the growth and progression of cancer through the
effect of glucocorticoids on cancer cells. Numerous studies have observed that cortisol treatment
leads to an increase in cancer cell invasiveness, dependent on the cell lines [18].
OXT was able to reverse the effects of cortisol through the induction of autophagy in the
SKOV3 cell line. This was confirmed through the noted increase of the Beclin-1 gene[49]. Of
note, this study used a high concentration of OXT, a dose that is many folds higher than
physiological levels. Since synthetic glucocorticoids can enhance cell survival in epithelial
tumors, such as ovarian cancer tumors, it is evident that OXT has an important role in the tumor
microenvironment.
Most importantly, to avoid nausea and vomiting post-surgery dexamethasone is given to
patients with ovarian cancer. Multiple studies found that ovarian cancer patients treated with
dexamethasone had an increase of pro-cancer cell survival genes at the tumor site [82-84].
Further, dexamethasone increased chemotherapy therapy resistance of ovarian carcinomas in
vivo, and increased basal growth of the xenografts[85, 86]. It is possible that glucocorticoids
interfere with chemotherapy effectiveness.
In this context, OXT may be effective through reversing the harmful effects of
glucocorticoids on cancer cell survival [49]. This opens new perspectives on OXTs role and
possible pharmacological use in ovarian cancer patients.
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Ovarian Cancer
Ovarian cancer (OVC) can be split into two groups, epithelial ovarian cancer and nonepithelial ovarian cancer, the latter comprising approximately 10% of ovarian cancers.
Approximately 240,000 people are diagnosed with ovarian cancer per year [87]. Although OVC
is less common than other cancers, it is one of the most deadly cancer types because unspecific
symptoms and the lack of biomarkers make it difficult to detect before metastasis and/or
mortality. The 5 year survival rate of epithelial ovarian cancer is 46%, stage III (tumor has
spread to the peritoneum outside of the pelvis) having the lowest long term survival rate at 35%
[87]
There are 5 major subtypes of OVC: High-grade serous carcinomas (HGSOC),
endometrioid carcinomas, ovarian clear cell carcinomas, mucinous carcinomas, and low grade
serous ovarian carcinomas [88]. In order to evaluate the anti-inflammatory effect of oxytocin on
ovarian cancer, four unique cell lines were used.
HGSOC is the most common ovarian cancer subtype, making up 70% of all epithelial
ovarian cancers [89]. This tumor is highly proliferative which could characterize it as
aggressive[90], and HGSOC tumors are known to be chemotherapy resistant [91].
In conclusion, the beneficial effects of social support for ovarian cancer patients may be
mediated through an increase of OXT in the tumor microenvironment. This study will evaluate
OXTs effect on pro-inflammatory biomarkers in ovarian cancer cells specifically. Further studies
are necessary to test and develop the clinical use of OXT.
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CHAPTER TWO: METHODS
Cell Culture
Cell lines used for this study were SCOV3/SKOV3, OVCA432, HEYA8, and OV432.
The cell line SCOV3 is a human ovarian cancer cell line that has epithelial like morphology.
The cell line was established in 1973 from the ascites of a 64-year-old Caucasian female with
adenocarcinoma of the ovary [92]. SKOV3 is unique as its immune phenotype most closely
resembles high grade serous, but also resembles clear cell (OCCC) histology. OCCC are similar
to endomertrioid and they are limited to the ovary at diagnosis. [92]
The next cell line used was OVCA432. This is another high grade serous ovarian cancer
cell line; there is variation in how these cells react, and is heterogenetic in nature[93]. OVCA432
cell lines are not well documented with varying reports on classifications. It is most reported to
be an ovarian serous adenocarcinoma. It has been reported that OVCA432 secretes a modest
amount of VEGF compared to other OVCA cell lines.[93]
HEYA8 cell line is a high-grade ovarian serous adenocarcinoma, which share lineage
with the HEY ovarian cancer cell line. This cell line is a moderately differentiated papillary
adenocarcinoma, and is considered one of the more aggressive cell lines based on survival time
and growth rate in pre-clinical models[94, 95].
OVCAR8 is considered a high grade ovarian serous carcinoma. This cell line is
documented to be similar to HEYA8, but is not as proliferative[95]. There is limited relevant
information available on this cell line.
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It should be noted, all four cell lines are widely used but there are significant
misidentifications, and many duplicates out there[96]. This is of importance to this study, as
results should be tested in-vivo.
OV432, SCOV3, OVCAR8, and HEYA8 cells will be maintained in a DMEM medium
containing 10% fetal bovine serum, 100 U/ml penicillin, 100 μg/ml streptomycin, and incubated
at 37°C in humidified 95% air-5% CO2 incubator. Cells were seeded at 10,000 cells/well in 24well tissue culture plates or into 60- or 100-mm dishes at 1 x 106 or 5 x 106 cells/dish,
respectively, and maintained on growth media until confluent. Cells will be incubated with OXT
at physiologically relevant levels (10-1000 pM) and processed for downstream application and
analysis.
PCR Experiments for Measuring IL-6 and OXTR mRNA Expression
The Rt-PCR experiment protocol follows the one set forth by the Mendez lab from
previous studies [77].
At the end of the incubation, cells will be washed three times with Dulbecco’s PBS. 350
µl of RLT Lysis Buffer (Qiagen RNeasy Kit, Qiagen, CA) will be added to each dish. Cells will
be detached by gentle scrapping and will be collected in QIAshredder spin columns placed in 2
ml collection tubes. Columns will be spun at maximum speed for 2 minutes and samples frozen
at -80°C until ready for RNA isolation. OXTR, OXT, IL-6, VEGF, or any other relevant mRNA
expression will be evaluated by real time polymerase chain reaction (RT-PCR). Total RNA
(optical density ratio of 260/280 nm, > 1.8) will be isolated using the RNeasy Kit (Qiagen, CA)
and stored at -80°C. After treatment with DNAse I (Applied Biosystems), the reverse
transcriptase reaction will be carried out by mixing 5–10 μg of total RNA in the presence of
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random oligomers (3.2 μg), MgCl2 (5 mM), deoxynucleotide mix (1 mM), Avian Myeloblastosis
Virus (AMV) reverse transcriptase (≥20 U), and RNase inhibitor (50 U) and incubated at 25°C
for 20 min, then at 42°C for 60 min, denatured at 99°C for 5 min and then cooled to 4°C for 5
min, resulting in cDNA synthesis. Quantitative gene expression of human OXTR, OXT, IL-6,
VEGF, or other genes of interest by RT-PCR will be performed with the TaqMan gene
expression assay (Applied Biosystems). Fifty nanograms of cDNA will be ampliﬁed with
TaqMan Universal PCR Master Mix and reactions will be run using universal cycling conditions
on an Applied Biosystems 7500 Real-Time PCR system. Samples will be analyzed in triplicate
for accuracy. The ΔΔCT (threshold cycle) method will be used to analyze changes in gene
expression in a given sample relative to another reference sample and expressed as the fold
change in gene expression. 18S mRNA will be used as the endogenous mRNA control. A nontemplate control will be performed to ensure that there will be no ampliﬁcation of genomic
DNA.
IL-6 Assay
Cells will be incubated after treatment under relevant experimental conditions for 6
hours, and then cell-free supernatants will be assayed by enzyme-linked immunosorbent assay
(ELISA) for IL-6 using commercially available reagents (BD Biosciences, San Diego, CA). As
an indicator of inflammation, all IL-6 secretion concentrations will be normalized to cell protein
concentration.
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OXT Extraction
Ovarian cancer cell lines SKOV3, HEYA8, and OVCAR8 were grown to confluence and
incubated for 16 hours, after which the media and cells were collected. Secretion of oxytocin was
measured in culture media after solid phase extraction by ELISA (Arbor Assays, Ann Arbor MI)
as previously described [43].
Statistical analyses.
Data were obtained from a minimum of three replicates from at least three separate
experiments and are presented as means ± SE. Results were compared by paired independent ttests or ANOVA (1- or 2-way) with post hoc Bonferroni correction. An α-level of 0.05 was
required for statistical significance.
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CHAPTER THREE: RESULTS
Oxytocin receptor expression
Expression of OXTR in four ovarian cancer cell lines was quantified by rt-PCR (Figure
1A). SCOV3, HEYA8, OVCAR8 all expressed detectable levels of OTR mRNA. Expression
was highest in OVCAR8, followed by SCOV3, HEYA8, and OXTR was not detectable in the
OV432 cells. OXTR protein expression was examined in these cells by immunoblotting (Figure
1B) and demonstrated two major immunoreactive bands with apparent molecular mass of 43 and
57 kDa This is consistent with the molecular weights of the native, unglycoslyated and the
mature glycosylated forms of the receptor, respectively [50]. Relative expression of the OXTR
protein, normalized to levels present in SCOV3 cells, demonstrated that HEYA8 cells exhibited
the highest expression levels, followed by OVCAR8, SCOV3, then OV432 cells. The 57kDa
band exhibited a twofold, and 1.5 fold increase of protein expression in HEYA8 cells and
OVCAR8 cells compared to SCOV3, respectfully. In the 43kDa band, HEYA8 had an eightfold
increase in protein expression compared to SCOV3, and OVCAR8 showed a fourfold increase in
protein expression compared to SCOV3. Notably, the relative expression of OXTR mRNA and
protein were not concordant in the different cells lines such that mRNA expression did not
predict protein expression.
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Effect of Norepinephrine on OXTR expression in human ovarian cancer cells
Norepinephrine (NE) is released from the sympathetic nervous system during stress, and
research show that chronic stress and other psychological conditions that increase NE production
are correlated with the spread and growth of cancer[18, 21, 97]. One consequence of
norepinephrine activation of adrenergic receptors on ovarian cancer cells is upregulation and
increased secretion of IL-6 (and VEGF) that can contribute to tumor proliferation and increased
tumor vascularization [3]. To evaluate the effect of norepinephrine as an inflammatory stimulus
on SCOV3, HEYA8, OVCAR8, and OV432 cells were treated with norepinephrine for 6 hours.
Following treatment, cellular mRNA was isolated to evaluate gene expression of IL-6 as a
marker of inflammation as well as effects on OXT and OXTR (Fig. 2). IL-6 mRNA expression
increased significantly with norepinephrine treatment in SCOV3, HEYA8, and OVCAR8, which
that confirms published results (p<.05) [2]. Previous data have revealed that OXTR is
upregulated in macrophages during an inflammatory response [98], thus the inflammatory effects
of norepinephrine on OXT and OXTR mRNA expression were examined. After NE treatment,
SCOV3 cells, OXTR expression was reduced by ~30%, and was not significantly changed in
OVCAR8 cells. However, OXTR expression was significantly increased (p<.01) by fivefold
after norepinephrine treatment in HEYA8 cells. OXT mRNA expression was not affected by NE
treatment in SCOV3 and OVCAR8. Further, OXT mRNA was undetectable in HEYA8 cells. In
the OV432 cell line mRNA for IL-6, OXTR and OXT was below the limit of detection.
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Effect of oxytocin on IL-6 secretion in catecholamine stimulated ovarian cancer cells.
Time course experiments in HEYA8 and SCOV3 cells showed that IL-6 secretion
increased over time under control conditions and was further stimulated by norepinephrine. For
later studies, the 6 hour time point was used since it represented the time point when stimulated
IL-6 secretion was increasing linearly with norepinephrine treatment. Previous studies have
shown that oxytocin inhibits proliferation of ovarian cancer [47], and OXT has been
demonstrated to be anti-inflammatory in vitro and in vivo in various models of inflammation [65,
75, 77, 99]. To evaluate potential anti-inflammatory effects of oxytocin in the ovarian cancer cell
lines, cells were treated with OXT in the presence or absence of norepinephrine for six hours and
IL-6 secretion was measured. The glucocorticoid dexamethasone was used as a positive control
for inhibiting inflammation [100]. Under control conditions, OXT treatment of cells reduced IL6 secretion in SCOV3 and HEYA8, but the difference was not statistically significant. OVCAR8
cells treated with OXT alone showed no change of IL-6 secretion compared to the control (all
p>.05). Incubation with norepinephrine (10 uM) significantly increased IL-6 secretion for all cell
lines tested. The addition of OXT resulted in an attenuation of IL-6 secretion in norepinephrinestimulated cells. Specifically, 1 nM oxytocin, in the presence of 10 µM norepinephrine,
decreased IL-6 secretion by 54% in SCOV3 cells (p < 0.05). IL-6 secretion also decreased by
27%in HEYA8 cells (p=.13), and by 15% in OVCAR8 cells, although these did not reach
statistical significance. Of note, OXT decreased IL-6 secretion at a substantially lower
concentration than the positive control dexamethasone (1nM vs. 100 µM). OV432 did not secrete
measureable amounts of IL-6 protein, so no further studies were performed with this cell line in
this context.
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Figure 3: The ovarian cell lines SCOV3 and HEYA8 were grown to confluence and then incubated for 6, 12, or 18 hours alone or
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secretion. Data are representative of two-three experiments per cell line
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Effect of Prostaglandins on IL-6 and OXT secretion
Previous results have demonstrated that the prostaglandins PGE and PGF2α can have
pro- or anti-inflammatory properties, respectively, in primary ovarian cell cultures [101] and that
PGF2α can stimulate OXT release from these cells[102]. The present study evaluated the effects
of these prostaglandins on IL-6 secretion, OXT secretion, and changes in mRNA of IL-6, OXT
and OXTR in ovarian cancer cells.
Time course experiments in HEYA8 and SCOV3 cells revealed that PGE treatment of
cells increased IL-6 secretion significantly in both cell lines (p<.05). When mRNA was
evaluated after PGE-treatment of cells for 6 hours, it was observed that IL-6 mRNA expression
increased twofold in each cell line (p<.05). In the HEYA8 cells, OXTR decreased by
approximately 25% (p>.05), while in SCOV3 there was no change in OXTR by PG treatment. In
addition, OXT secretion from these cells was also measured after PGE treatment. PGE did not
effect OXT secretion in either cell line compared to control levels of secretion.
Results of the time course experiments in HEYA8 and SCOV3 displayed that treatment with
PGF2α had no effect on IL-6 secretion. When mRNA was evaluated for the PGF2α treated cells,
SCOV3 had a significant increase in OXT mRNA (p<.05), although this did not translate to
increased OXT secretion. Further, IL-6 mRNA expression decreased by approximately 20%,
though this value did not reach statistical significance. In HEYA8 cells, the PGF2α treatment had
no effects on IL-6, OXT, and OXTR mRNA expression, as well as OXT secretion, compared to
controls.
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CHAPTER FOUR: DISCUSSION
The current study was initiated by the observation that ascites fluid from subjects with
ovarian cancer had elevated levels of oxytocin compared to plasma levels. Patients in the highest
quartile of ascites fluid oxytocin were correlated (via a trend) to a lower cancer stage and
improved survival at 5 years (Lutgendorf et al, personal communication). Based on those results
we evaluated the OXT/OXTR pathway in several ovarian cancer cell lines to evaluate potential
anti-inflammatory effects of OXT that could modulate cancer cell microenvironment.
This in-vitro study revealed that oxytocin has anti-inflammatory effects on high-grade
serous ovarian cancer cell lines and that oxytocin decreased norepinephrine induced IL-6
secretion in these cells. By reducing the stress-induced inflammatory process in ovarian cancer
cells, these data suggest that oxytocin may have a significant role in the ovarian cancer
microenvironment.
Oxytocin receptor protein and mRNA were identified in ovarian cancer cell lines
SCOV3, HEYA8, OVCAR8 and OV432, confirming previous results [47]. A novel finding was
the demonstration of the discordance between mRNA and protein expression of OXT/OXTR in
these ovarian carcinoma cells. This may be due to disparate regulation of the receptor, either at
the mRNA or protein level. The association between mRNA and protein levels is still being
investigated and indicates a complex regulation of the receptor. This phenomena provides an
avenue for future research.
All four cell lines studied expressed an immunoreactive band of OXTR consistent with
the known MW of the mature and immature (unglycosylated) forms of the receptor. Studies in
uterine issues and results from our lab have previously identified different MW forms of the

30

oxytocin receptor [77, 103]. It is possible that different glycosylation sites on the receptor can
have a role in ligand binding and affinity. While possible, other in vitro studies observed that the
disruption of these glycosylation sites did not affect receptor localization to the plasma
membrane or ligand binding to the receptor.
Inflammation resulting from stress plays an important role in ovarian cancer progression
and angiogenesis[3, 18]. The current study examined the effects of oxytocin on specific aspects
of this disease process. Oxytocin decreased norepinephrine stimulated IL-6 secretion by 54% in
SCOV3 cells, 27%in HEYA8 cells, and by 15% in OVCAR8 cells. This is a novel finding, and is
interesting in light of the fact that oxytocin receptor gene contains an IL-6 response element that
upregulates the receptor in response to inflammation. This phenomenon has been observed in
other cell types, including immune cells, suggesting that oxytocin may have a broader and an
active role in the tumor microenvironment other than the ovarian cancer cells.
It has been reported that PGs can modulate inflammation and OXT secretion in
normal/primary ovarian cells in culture, thus we evaluated whether PGS influenced OXT/OXTR
and IL-6 in the ovarian cancer cell lines. Data showed that PGE2 induced IL-6 mRNA
production and protein secretion. Neither PGE2, nor PGF2α altered OXT secretion or mRNA.
These results suggest that OXT secretion in these cell lines respond differently to PGs than
primary ovarian cells.
Studies in the past from our laboratory revealed that a stable social environment,
characterized by increased affiliative social behavior, slowed the progression of atherosclerosis
in an animal model [99, 104]. A more recent study showed that oxytocin receptors were present
in endothelial cells, smooth muscle cells, monocytes, and macrophages, and that treatment with
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oxytocin was responsible for significant decreases in oxidative stress and inflammation[77]. This
suggests that oxytocin may slow the progression of atherosclerosis, the underlying inflammatory
process in cardiovascular disease. Clinical studies for those diagnosed with cancer found that
social support increased survival time/advantage. A similar anti-inflammatory mechanism
appears to be present in ovarian cancer cells. There have been a substantial amount of studies
that link social behavior to oxytocin, and the findings of the current study proposes that
elevations in peripheral or local oxytocin in the ovarian cancer microenvironment, as a result of
social environment, could work directly on ovarian cancer cells to slow the progression of the
disease. Further studies will examine the relationship between mRNA and protein expression of
OXT/OXTR, a pre-clinical model to examine oxytocin for potential pharmacological use, and
further mechanistic studies to understand this unique phenomenon.
Future research could look into the male reproductive system. It has been speculated that
oxytocin could be used as a biomarker for prostate cancer[105]. Similar to ovarian cancer
patients, prostate cancer patients have serum and prostatic oxytocin levels that are higher than
normal[105]. Further, because of the known effects of oxytocin in healthy pregnant women,
future research could look at how this increase in oxytocin in ovarian cancer patients effects the
individual in terms of pain, lactation, and other downstream effects caused by oxytocin.
Currently, there is no pharmaceutical use for oxytocin aside from childbirth. Due to its antiinflammatory effects in a number of models, oxytocin may be used more extensively in the
future.
In summary, oxytocin receptors were identified in cultured ovarian cancer cells lines
SCOV3, HEYA8, OVCAR8, and OV432. Norepinephrine induced IL-6 secretion was attenuated
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in the cell lines by treatment with oxytocin. These novel findings suggest that oxytocin has the
potential to be a pharmacological option in the future for ovarian cancer patients, to be a possible
biomarker for ovarian cancer patients, and demonstrates the importance of social support being
in the protocol for management of this disease.
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